Global Medical Marijuana Market Report 2022-2030
Dublin – The global medical marijuana market size is expected to reach USD 65.8 billion by 2030 and is expected to expand at a CAGR of 21.6%
The major factors attributed to the industry growth are the rapid adoption of cannabis in therapeutic applications and a surge in the number of countries legalizing the usage of medical marijuana.
As per numerous studies, cannabis has shown positive results in the treatment of chronic diseases. Thus, with the growing penetration of chronic disease throughout the globe, the industry is expected to see a steep rise in demand. For instance, as per the data released by the WHO, the chronic disease burden was expected to reach 57% by 2020. The growing research and development activities in the industry are also expected to drive the growth in demand.
Additionally, various factors such as a rise in disposable income, increasing social acceptance of cannabis, and growth in awareness regarding the benefits of the product, along with improvements in intellectual property rights of cannabis are some of the major factors that are expected to fuel the growth of the industry.
Key players are coming together on strategic initiatives such as mergers & acquisitions, collaborations, partnerships, funding & investments, and innovative product developments & launches to expand their expertise & product portfolio. This also fuels the industry’s growth.
For instance, in March 2021, Germany’s largest pharmaceutical company, Stada entered the medical marijuana market by launching its two flower products, and further, the company has plans to offer five flower products along with three extracts with different compositions of CBD and THC.
One of the major factors that restrict industry growth is the strict regulation policy. To date, FDA has not allowed the marketing usage of cannabis for the treatment of any disease or condition. Although, the organization has approved one cannabis-derived drug product: Epidiolex (cannabidiol), and three synthetic cannabis-related drug products: Marinol (dronabinol), Syndros (dronabinol), and Cesamet (nabilone). These permitted drug products are only available with a prescription from a licensed healthcare provider.
Medical Marijuana Market Report Highlights
- The market size is anticipated to be valued at USD 65.8 million by 2030, owing to the growing legalization of medical marijuana in various countries
- In 2021, the oil and tinctures segment dominated the market owing to its growing medical usage for the treatment of chronic pains, cancer, neurological disorders, and others
- Chronic pain segment dominated in 2021. The growing number of clinical trials with marijuana to treat neuropathic and chronic pain is one of the key indicators, which highlights the rising usage of cannabis in pain management over the coming few years
- North America dominated in 2021 owing to the presence of major players, the increasing rate of cannabis legalization in the U.S., and the launch of new products
- Aurora Cannabis
- Canopy Growth Corporation
- Aphria, Inc.
- Maricann Group, Inc.
- Tikun Olam, Ltd.
- MedReleaf. Corp.
- GW Pharmaceuticals plc.
- Cannabis Sativa, Inc.
- Medical Marijuana, Inc.
Key Topics Covered:
Chapter 1 Methodology and Scope
Chapter 2 Executive Summary
2.1 Medical Marijuana Market Outlook, By Revenue (USD Million)
Chapter 3 Medical Marijuana Market Variables, Trends and Scope
3.1 Penetration & Growth Prospect Mapping
3.2 Product Pipeline Analysis, by Stage
3.3 Technology Overview
3.3.1 Technology timeline
3.4 Regulatory Framework
3.5 Market Dynamics
3.5.1 Market driver analysis
3.5.2 Market restraint analysis
3.6 Medical Marijuana Market Analysis Tools
3.6.1 Industry analysis – Porter’s
3.6.2 PESTEL Analysis
3.6.3 Global Marijuana Demand-Supply Analysis
3.6.4 Global Marijuana Trade Route
3.6.5 Patient Pool Analysis
Chapter 4 Medical Marijuana Market: Product Type Estimates & Trend Analysis
4.1 Definitions & Scope
4.2 Medical Marijuana Market Share by Product Type
4.3 Segment Dashboard
4.4.1 Flower market estimates and forecasts, 2017 – 2030 (USD Million)
4.5 Oil & Tinctures
Chapter 5 Medical Marijuana Market: Application Estimates & Trend Analysis
5.1 Definitions & Scope
5.2 Medical Marijuana Market Share by Application
5.3 Segment Dashboard
5.4.1 Cancer market estimates and forecasts, 2017 – 2030 (USD Million)
5.5 Chronic Pain
5.6 Depression & Anxiety
5.12 Multiple Sclerosis
5.14 Amyotrophic Lateral Sclerosis
5.15 Alzheimer’s Disease
5.16 Post-Traumatic Stress Disorder (PTSD)
5.17 Parkinson’s Disease
Chapter 6 Medical Marijuana Market: Regional Estimates & Trend Analysis, by Product
6.1 Market Size, & Forecasts, and Trend Analysis, 2017 to 2030:
220.127.116.11 Market estimates and forecasts, by product type, 2017 – 2030 (USD Million)
18.104.22.168 Market estimates and forecasts, by application 2017 – 2030 (USD Million)
6.7.1 Czech Republic
6.17.1 New Zealand
Chapter 7 Competitive Landscape
7.1 Company Overview
7.2 Financial Performance
7.3 Product Benchmarking
7.4 Strategic Initiatives
(This information is primarily sourced from Research and Markets. Highly Capitalized has neither approved nor disapproved the contents of this news release. Read our Disclaimer here).
California Cannabis Brand, Rose, Teams Up with Kiva Sales and Service to Expand Product Line
LOS ANGELES-- Rose, California's cannabis brand, announced today an exclusive partnership with Kiva Sales and Service (KSS), a top sales and distribution platform that offers dispensaries a curated selection of the best brands in the ...
Australian Nurses Call for Medicinal Cannabis Education in Undergraduate Degrees
The group wants education about the endocannabinoid system included in undergraduate nursing degrees. Seven years ago, the Federal Parliament passed legislation to legalise medicinal cannabis in Australia. Since then, most cannabis medications have been classified ...
Psychedelic Firm Reunion Neuroscience Sues Mindset Pharma for Patent Infringement and Breach of Contract
LOS ANGELES-- Clinical research firm Reunion Neuroscience Inc. has filed a lawsuit against Mindset Pharma Inc. in federal court, alleging that the latter copied its psychedelic formula and presented it as its own invention while ...